US Pediatric Vaccine Market to Reach Nearly USD 10 Bn by 2024, States DPI Research in Its New Report Available at MarketPublishers.com
30 Oct 2017 • by Natalie Aster
LONDON – The US pediatric vaccine market is poised to be worth close to USD 10 billion by end-2024. Factors like increased awareness about the disease, rising public acceptance, surging focus of governments on immunisation programmes and intensive government investment in the development of vaccines, amid others, are propelling the market growth.
GlaxoSmithKline(GSK), Sanofi Pasteur, Merck & Co., Pfizer and Grifols, are some of the leading players in the US pediatric vaccine market.
New research publication “United States Pediatric Vaccine Market 2017” created by DPI Research & Marketing Solutions provides a deep and unbiased examination of the market on a national level.
The report provides detailed market segmentation, uncovers details about the market size, revenue and volume figures, and provides exhaustive forecasts through to 2024. It thoroughly evaluates the 10 major pediatric vaccines by indication, offering a comprehensive analysis of administered doses, number of children vaccinated and the market size. Furthermore, the research offers a detailed assessment of the main growth drivers and limiters of the country’s pediatric vaccine market. The report presents detailed profiles of the 5 leading players in the domestic pediatric vaccine market; the players are analysed by various parameters like business overview, product portfolios, and latest trends and developments. The study includes a detailed 7-year forecast showing how the marketplace is predicted to evolve in the years ahead.
More new research reports by DPI Research can be found in the publisher’s catalogue at MarketPublishers.com.